-
公开(公告)号：US06624200B2
公开(公告)日：2003-09-23
申请号：US09877218
申请日：2001-06-11
IPC分类号： A01N3302
CPC分类号： A61K9/006 , A61K9/2027 , A61K9/2054
摘要： A bioadhesive composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).
-
公开(公告)号：US06593317B1
公开(公告)日：2003-07-15
申请号：US09833259
申请日：2000-10-17
IPC分类号： A61K3157
CPC分类号： A61K31/57 , A61K9/0034 , A61K9/7023 , A61K47/32 , Y10S514/944 , A61K31/565 , A61K2300/00
摘要： The present invention teaches that daily, cyclical vaginal delivery of progestin may be used to provide regular, predictable withdrawal bleeding during hormone replacement therapy. The present invention also teaches that constant administration of progestin in a water-insoluble, water-swellable cross-linked polycarboxylic acid polymer may be used to maintain amenorrhea. Either regimen is accompanied by a significant decrease in adverse side effects.
摘要翻译： 本发明教导，孕激素替代治疗期间可以使用孕激素的每日周期性阴道分娩来提供规则的，可预测的撤出性出血。 本发明还教导了在水不溶性的水溶胀性交联聚羧酸聚合物中不断施用孕激素以维持闭经。 两种方案都伴随着副作用的显着降低。
-
公开(公告)号：US06818672B1
公开(公告)日：2004-11-16
申请号：US10089796
申请日：2002-07-24
IPC分类号： A01N3302
CPC分类号： A61K47/32 , A61K9/0034 , A61K9/2027 , A61K31/135 , A61K31/137 , Y10S514/967
摘要： The present invention concerns compositions and methods for using a &bgr;-adrenergic agonist for treating endometriosis, for treating infertility, and for improving fertility. The present invention further concerns formulating such a composition or method in such a way as to provide therapeutically sufficient levels of the &bgr;-adrenergic agonist locally while avoiding adverse systematic concentrations in the host, thereby minimizing or avoiding adverse side effects.
摘要翻译： 本发明涉及使用β-肾上腺素能激动剂治疗子宫内膜异位症，治疗不孕症和改善生育能力的组合物和方法。 本发明还涉及以这样的方式配制这样的组合物或方法，以便局部地提供治疗上足够水平的β-肾上腺素能激动剂，同时避免宿主中不利的系统浓度，从而最小化或避免不良副作用。
-
公开(公告)号：US06306914B1
公开(公告)日：2001-10-23
申请号：US09170326
申请日：1998-10-13
IPC分类号： A01N2500
CPC分类号： A61K31/57 , A61K9/0034 , A61K9/7023 , A61K47/32 , Y10S514/944 , A61K31/565 , A61K2300/00
摘要： The present invention teaches that daily, cyclical vaginal delivery of progestin may be used to provide regular, predictable withdrawal bleeding during hormone replacement therapy. The present invention also teaches that constant administration of progestin in a water-insoluble, water-swellable cross-linked polycarboxylic acid polymer may be used to maintain amenorrhea. Either regimen is accompanied by a significant decrease in adverse side effects.
摘要翻译： 本发明教导，孕激素替代治疗期间可以使用孕激素的每日周期性阴道分娩来提供规则的，可预测的撤出性出血。 本发明还教导了在水不溶性的水溶胀性交联聚羧酸聚合物中不断施用孕激素以维持闭经。 两种方案都伴随着副作用的显着降低。
-
5.发明申请VAGINALLY ADMINISTERED ANTI-DYSRHYTHMIC AGENTS FOR TREATING PELVIC PAIN 审中-公开用于治疗皮肤疼痛的VAGINALLY ADMISISED抗精神病药公开(公告)号：US20080182841A1
公开(公告)日：2008-07-31
申请号：US11849862
申请日：2007-09-04
IPC分类号： A61K31/554 , A61K31/165 , A61P13/00 , A61P29/00 , A61K31/195
CPC分类号： A61K9/0034 , A61K9/2027 , A61K31/00 , A61K31/137 , A61K31/165 , A61K31/192 , A61K31/195 , A61K31/245 , A61K31/554 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38
摘要： The invention relates to a pharmaceutical composition for relieving pelvic pain or infertility associated with uterine dysrhythmia. The composition includes a locally-administered anti-dysrhythmic treating agent and a bioadhesive extended-release carrier. The composition may be delivered in an extended release formulation that includes a bioadhesive, water-swellable, water-insoluble, cross-linked polycarboxylic acid polymer, such as polycarbophil. The treating agent may be a local anesthetic, such as lidocaine. The invention also relates to a method of treating or preventing pelvic pain, or treating or improving infertility, by inserting a mixture of an anti-dysrhythmic treating agent and a bioadhesive carrier into the vagina of the patient to be treated.
摘要翻译： 本发明涉及一种用于缓解与子宫心律失常相关的盆腔疼痛或不育症的药物组合物。 组合物包括局部施用的抗心律失常治疗剂和生物粘附性延长释放载体。 组合物可以在包含生物粘附剂，水溶胀性，水不溶性交联聚羧酸聚合物如聚卡波非的缓释制剂中递送。 处理剂可以是局部麻醉剂，例如利多卡因。 本发明还涉及通过将抗心律失常治疗剂和生物粘附性载体的混合物插入待治疗患者的阴道中来治疗或预防盆腔疼痛或治疗或改善不育症的方法。
-
6.发明授权Bioadhesive progressive hydration tablets and methods of making and using the same 有权生物粘合剂逐步水合片及其制备和使用方法公开(公告)号：US06248358B1
公开(公告)日：2001-06-19
申请号：US09379310
申请日：1999-08-23
IPC分类号： A61K920
CPC分类号： A61K31/568 , A61K9/0034 , A61K9/006 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059
摘要： A bioadhesive tablet wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the tablet, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the tablet is available for absorption (bioavailable).
摘要翻译： 生物粘附片剂，其中活性成分可以被保护免受水或周围环境的影响，从而保护其不受代谢或由水分，酶或pH影响引起的其它降解，并且仅以受控的速率使其生物可利用。 活性成分可以在制造过程中受到保护，并且更重要的是可以防止水分和直接的化脓性环境，直到患者施用片剂，然后仅以缓慢和受控的速率。 正是通过这种进行性水合过程，活性成分在给药后保持多个小时。 也是通过进行性水合的过程来实现控制和持续释放，因为只有作为片剂的水合（水性）级分的活性成分的那部分可用于吸收（生物可利用的）。
-
公开(公告)号：US6054447A
公开(公告)日：2000-04-25
申请号：US240610
申请日：1999-02-01
IPC分类号： A61K31/565 , A61K31/57 , A61K31/56
CPC分类号： A61K31/57
摘要： The present invention provides a method of treating or reducing ischemia or incidence of cardiovascular events by administering progesterone. Progesterone, unlike synthetic progestins, has been demonstrated to supplement, rather than to decrease, the beneficial effects of estrogen therapy on myocardial ischemia in females.
摘要翻译： 本发明提供了通过施用孕酮来治疗或减少心血管事件的缺血或发生的方法。 黄体酮与合成孕激素不同，已被证明可以补充而不是减少雌激素治疗对女性心肌缺血的有益作用。
-
公开(公告)号：US5667492A
公开(公告)日：1997-09-16
申请号：US319495
申请日：1994-10-07
CPC分类号： A61K9/0034 , A61K47/32 , Y10S424/14 , Y10S514/843 , Y10S514/967
摘要： The present invention provides a composition and use of a composition comprising a bioadhesive cross-linked polycarboxylic acid polymer formulation that enables the use of relatively low mounts of anti-STD infectants, such as N-9, to be used to prevent infection by STDs without causing the irritation to genital tissue that often accompanies higher doses of anti-STDs. The bioadhesive polymer maintains greater contact between the anti-STD agent and the infectant for a much greater period of time, enabling a lower concentration to act longer on the infectant, when compared to currently-available commercial applications containing N-9. Such delivery will enable a safe and non-irritating decrease in the risk of infection with STDs, including HIV.
摘要翻译： 本发明提供组合物和组合物的组合物，其包含生物粘附性交联聚羧酸聚合物制剂，其能够使用相对低的抗STD感染剂如N-9，以防止STD感染而没有 导致对经常伴随更高剂量的抗STD的生殖器官组织的刺激。 与目前可用的含有N-9的商业应用相比，生物粘附聚合物在更长的时间段内保持了抗STD剂和感染剂之间更大的接触，使得较低的浓度在感染剂上起作用时间更长。 这种分娩将可以安全和无刺激地降低包括艾滋病毒在内的性传播疾病感染的风险。
-
公开(公告)号：US08765177B2
公开(公告)日：2014-07-01
申请号：US11431611
申请日：2006-05-11
CPC分类号： A61K9/006 , A61K9/0031 , A61K9/0034
摘要： A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).
摘要翻译： 生物粘附控制的延长释放的进行性水合组合物，其中活性成分可以被保护免受水或周围环境的影响，从而保护其免受代谢或由水分，酶或pH影响引起的其它降解，并且仅在受控的 率。 活性成分可根据需要或需要在制造过程中得到保护，并且更重要的是可以保护免受潮湿和直接的败血症环境，直到患者施用组合物，然后仅以缓慢和受控的速率 。 正是通过这种进行性水合过程，活性成分在给药后保持多个小时。 还通过进行水合的过程，控制和持续释放是实现的，因为只有作为组合物的水合（水）部分的活性成分的那部分可用于吸收（生物可利用的）。
-
公开(公告)号：US08425892B2
公开(公告)日：2013-04-23
申请号：US10423920
申请日：2003-04-28
IPC分类号： A61K31/74
CPC分类号： A61K47/32 , A61K9/0034 , A61K9/2027 , A61K31/00 , A61K31/137 , A61K31/192 , A61K31/245 , A61K31/554 , A61K47/10 , A61K47/12 , A61K47/38
摘要： The present invention relates to a delivery system for pharmaceutical compositions relying in part on an ionic interaction to control and facilitate release of the treating agent. More specifically, the invention relates to an extended controlled-release system having an ionic treating agent and an ionic polymer, wherein the polymer is sufficiently ionized to release the treating agent in a controlled manner over an extended period of time and the composition does not require an emulsion system for administering the treating agent.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.02 秒)
